Abbott and Enanta’s ABT-450/r Phase 2 study results against HCV presented at EASL meeting Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.D., chief of hepatology at the Liver Transplant and Disease Center at Cedars-Sinai INFIRMARY in Los Angeles, and one of the investigators for the scholarly research online pharmacy . Abbott is attempting to transform treatment options for patients with HCV disease by investigating ways to simplify treatment and increase cure rates, said Scott Brun, M.D., divisional vice president, infectious disease advancement, Abbott. Related StoriesResearchers successfully test new way for rapid medical diagnosis of Ebola in GuineaRNA profiles of tumor-educated platelets may diagnose cancer, recognize potential therapeutic approachesUltragenyx, Arcturus sign agreement to develop mRNA therapeutics to certain rare illnesses We continue being encouraged by the outcomes for ABT-450/r and the potential it holds for treatment-experienced and treatment-naive individuals with HCV, stated Jay Luly, Ph.D., president and ceo, Enanta Pharmaceuticals.
International Nutritionals Sales Improved 15.6 Percent. Firm Confirms Earnings-Per-Talk about Outlook for 2007 and 2008. September 30 Abbott announced financial outcomes for the 3rd quarter ended, 2007. Diluted revenue per talk about, excluding specified items, were $0.67, above Abbott’s previously announced assistance selection of $0.64 to $0.66. Diluted earnings per share under Generally Approved Accounting Principles were $0.46. Predicated on its strong results year to date, Abbott is confirming its 2007 earnings-per-share outlook and raising the low end of its prior guidance range. Furthermore, the company is normally confirming its outlook for an accelerating rate of earnings-per-share development in 2008 compared to 2007.